Tune 401 | YesPress

Browse all tags

ceo2908 saas2410 ai1721 fintech1452 founder1251 b2b1071 b2b saas885 san francisco822 co-founder814 san-francisco796 y combinator768 startup729 machine learning663 enterprise software624 stanford603 series a590 venture capital576 biotech543 cybersecurity532 healthtech479 new york startup469 enterprise-software445 ai agents442 generative ai436 digital health434 silicon-valley389 agentic ai388 d2c384 silicon valley380 ecommerce378 machine-learning373 startup founder360 california351 entrepreneur350 new york347 venture-capital340 edtech339 climate tech327 newsletter321 mit302 proptech301 robotics293 y-combinator279 san francisco startup278 series b270 enterprise ai269 developer tools264 computer vision254 oncology252 open-source247 series-a243 harvard242 sustainability240 supply chain232 enterprise230 iot230 biotechnology223 compliance222 workflow automation222 telehealth217 founder ceo216 healthcare212 insurtech211 developer-tools210 blockchain209 devops208 medical devices206 series-b206 forbes 30 under 30194 llm192 logistics190 uc berkeley189 author188 deep tech187 clean energy186 generative-ai185 web3184 a16z183 cloud183 drug discovery182 life sciences176 artificial intelligence175 no-code175 b2c173 manufacturing173 payments170 general partner169 healthcare ai169 serial entrepreneur167 seed funding164 open source162 crm161 podcast160 hardware159 unicorn158 digital transformation157 predictive analytics152 automation151 crypto150 infrastructure150

Often tagged with

epigenetics1 epigenome editing1 gene regulation1 genetic medicine1 biotechnology1 gene therapy1 hepatitis b1 tempo platform1 cell reprogramming1 regenerative medicine1 epigenetic silencing1 crispr1 precision medicine1 longevity1

Tagged: tune-401

1 result

Sort

Health · Hardware · Enterprise

Tune Therapeutics

Tune Therapeutics is a genetic-medicine company building tools to turn genes up or down without cutting DNA. Its TEMPO epigenetic-editing platform tunes gene expression the way a sound engineer rides a fader - reversible, programmable, and precise. Spun out of Duke's Gersbach Lab, Tune raised over $175M in Series B financing in January 2025 and is running first-in-human trials of TUNE-401, an epigenetic silencer for chronic hepatitis B, with the larger ambition of editing the genome's software to extend human healthspan.

epigenetics · epigenome editingRead →